178 related articles for article (PubMed ID: 35970534)
1. Disease Flare of Systemic Lupus Erythematosus in Patients With Endstage Renal Disease on Dialysis.
Kim YE; Choi SJ; Lim DH; Kim H; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
J Rheumatol; 2022 Oct; 49(10):1131-1137. PubMed ID: 35970534
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
[TBL] [Abstract][Full Text] [Related]
3. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients.
Wafa A; Hicham H; Naoufal R; Hajar K; Rachid R; Souad B; Mouna M; Zoubida MT; Mohamed A
Clin Rheumatol; 2022 Jul; 41(7):2021-2033. PubMed ID: 35179662
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with active systemic lupus erythematosus after endstage renal disease.
Szeto CC; Li PK; Wong TY; Leung CB; Lui SF
J Rheumatol; 1998 Aug; 25(8):1520-5. PubMed ID: 9712094
[TBL] [Abstract][Full Text] [Related]
5. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
6. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.
Tselios K; Gladman DD; Su J; Urowitz MB
J Rheumatol; 2016 Mar; 43(3):552-8. PubMed ID: 26773121
[TBL] [Abstract][Full Text] [Related]
8. Analysis of lupus activity in end-stage renal disease treated by hemodialysis.
Okano K; Yumura W; Nitta K; Uchida K; Ohnuki T; Kawashima A; Nihei H
Intern Med; 2001 Jul; 40(7):598-602. PubMed ID: 11506299
[TBL] [Abstract][Full Text] [Related]
9. Long-term renal survival of paediatric patients with lupus nephritis.
Demir S; Gülhan B; Özen S; Çeleğen K; Batu ED; Taş N; Orhan D; Bilginer Y; Düzova A; Ozaltin F; Topaloğlu R
Nephrol Dial Transplant; 2022 May; 37(6):1069-1077. PubMed ID: 33826705
[TBL] [Abstract][Full Text] [Related]
10. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
[TBL] [Abstract][Full Text] [Related]
11. Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study.
Torres-Ruiz J; Barrera-Vargas A; Ortiz-Hernández R; Alcocer-Varela J; Ponce-de-León A; Gómez-Martín D
Lupus; 2018 Feb; 27(2):312-318. PubMed ID: 28699377
[TBL] [Abstract][Full Text] [Related]
12. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
13. Reduced Rate of Disease Flares in Japanese Patients with Systemic Lupus Erythematosus: An Altered Balance between the Use of Glucocorticoids and Immunosuppressants in Recent Decades.
Imaizumi C; Ogura T; Inoue Y; Takakura Y; Katagiri T; Takenaka S; Ito H; Mizushina K; Hirata A; Kameda H
Intern Med; 2022; 61(21):3189-3196. PubMed ID: 36328585
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
[TBL] [Abstract][Full Text] [Related]
15. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
[TBL] [Abstract][Full Text] [Related]
16. Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study.
Minowa K; Amano H; Ando S; Watanabe T; Ogasawara M; Kawano S; Kaneko T; Morimoto S; Yamaji K; Tamura N; Tokano Y; Hashimoto H; Takasaki Y
Mod Rheumatol; 2017 Jan; 27(1):72-76. PubMed ID: 27539069
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study.
Nannini C; Crowson CS; Matteson EL; Moder KG
Lupus; 2009 Apr; 18(5):394-9. PubMed ID: 19318390
[TBL] [Abstract][Full Text] [Related]
18. Low serum uromodulin levels and their association with lupus flares.
David BL; Ivan GJ; Emilio PE; Daniela MJ; Betsabe CH; Luisa VM; Selene FN; Guadalupe AEA; Miriam SA; Alfredo C; Arturo NC; Mercedes HD; German CE; Gonzalez-Lopez L
PLoS One; 2022; 17(10):e0276481. PubMed ID: 36301848
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE.
Nossent HC; Swaak TJ; Berden JH
Am J Med; 1990 Aug; 89(2):169-74. PubMed ID: 2382665
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment with Belimumab in a Patient with Refractory Systemic Lupus Erythematosus after Initiation of Hemodialysis: Considering the Synergistic Effect of Belimumab and Immunological Burn-Out Phenomenon in End-Stage Renal Disease Patients on Hemodialysis.
Karasawa K; Ogura S; Takabe T; Miyabe Y; Iwabuchi Y; Akiyama K; Sato M; Moriyama T; Uchida K; Nitta K
Blood Purif; 2022; 51(2):182-188. PubMed ID: 33895749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
